Not Logged In

Emergent BioSolutions, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and commercialization of specialized products for use in defense and commercial markets in the United States and internationally. The company operates in two segments, Biodefense and Biosciences. It markets BioThrax, an FDA licensed vaccine for the prevention of anthrax disease; and RSDL (decontamination lotion) product for removal or neutralization of chemical warfare agents from the skin. The company's development pipeline includes Anthrivig (Human Anthrax Immunoglobulin), a polyclonal anthrax therapeutic candidate; PreviThrax, a recombinant anthrax vaccine candidate, NuThrax (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant); BioThrax with a novel adjuvant; and Thravixa (Fully Human Anthrax Monoclonal Antibody), a therapeutic being studied for use against symptomatic anthrax infection. In addition, it develops TRU-016, a humanized anti-CD37 therapeutic candidate, based on its ADAPTIR (Modular Protein Technology) platform that is in Phase I/II clinical trials to treat chronic lymphocytic leukemia. Further, the company develops preclinical product candidates targeted for solid tumors, inflammatory bowel disease, graft versus host disease, rheumatoid arthritis, and a human vaccine to protect against influenza caused by a range of circulating H5 influenza strains. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Rockville, Maryland.